Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf
Links:
Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort - Associati…
https://acrabstracts.org/abstract/gastroesophageal-reflux-disease-in-an-austral…
14-11-2022
